13F reference period
Q2 2026
Security Snapshot
CITIUS ONCOLOGY, INC. - Common Stock (CTOR) Institutional Ownership
CUSIP: 17331Y109
13F Institutional Holders and Ownership History from Q3 2024 to Q3 2026
Institutions Reporting
19
Shares (Excl. Options)
14.15M
Full value: 14,145,277 · shares · 30 Jun 2026Price
$0.65
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- CTOR on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 14,145,277
- Total 13F value
- $9,195,137
- Portfolio coverage rank
- 0%
- Share change
- -102,361
- Value change
- -$65,363
- Number of holders
- 19
- Shares outstanding
- 93,629,159
- SEC-reported price per share
- $0.84
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- CTOR - CITIUS ONCOLOGY, INC. - Common Stock is tracked under CUSIP 17331Y109.
- 19 institutions reported positions in Q2 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 13 to 19 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$8.83M
Full value: $8,828,728 · USD · 31 Mar 2026.$9.2M
Full value: $9,195,137 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 19 institutions filings for Q2 2026.
Security key
17331Y109
13F reference period
Q2 2026
13F holders
19
13D/G owners
2
CIK / CUSIP context first
Open Q2 2026 holders
CTOR full holder history
CITIUS ONCOLOGY, INC. SEC filings
CITIUS ONCOLOGY, INC. company facts
CITIUS ONCOLOGY, INC. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 17331Y109:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
CTOR
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Citius Pharmaceuticals, Inc. | 71% | -8.8% | $59,444,654 | 66,049,615 | 0% | Citius Pharmaceuticals, Inc. | 15 May 2026 | |
| ARMISTICE CAPITAL, LLC | 10% | 0% | $6,547,487 | +$37,545 | 9,353,553 | +0.58% | Armistice Capital, LLC | 30 Jun 2026 |
As of 30 Jun 2026,
19
institutional investors reported holding
shares of
CITIUS ONCOLOGY, INC. - Common Stock (CTOR).
This represents
15%
of the company’s total
outstanding shares.
14.15M
Full value: 14,145,277 · shares · 30 Jun 202693.63M
Full value: 93,629,159 · shares · Stored outstanding share count13F concentration
Top 20 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
15%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 9.3% | 8,705,589 | -5.3% | 0.16% | $5,659,503 |
| BANK OF AMERICA CORP /DE/ | 4.1% | 3,835,160 | 0% | 0% | $2,492,854 |
| VANGUARD CAPITAL MANAGEMENT LLC | 0.58% | 546,325 | +2.2% | 0% | $355,111 |
| UBS Group AG | 0.36% | 334,619 | +808% | 0% | $217,502 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.26% | 245,407 | -7.3% | 0% | $159,538 |
| VANGUARD FIDUCIARY TRUST CO | 0.13% | 121,910 | 0% | 0% | $79,242 |
| IFP Advisors, Inc | 0.11% | 107,424 | 0% | 0% | $69,836 |
| CITADEL ADVISORS LLC | 0.1% | 90,586 | 0% | $58,890 | |
| NORTHERN TRUST CORP | 0.05% | 45,746 | 0% | 0% | $29,739 |
| STATE STREET CORP | 0.05% | 42,900 | 0% | 0% | $27,889 |
| Virtu Financial LLC | 0.02% | 21,877 | 0% | $14,000 | |
| XTX Topco Ltd | 0.02% | 20,638 | 0% | $13,417 | |
| Tower Research Capital LLC (TRC) | 0.01% | 13,816 | 0% | $8,982 | |
| Arkadios Wealth Advisors | 0.01% | 11,666 | 0% | 0% | $7,584 |
| OSAIC HOLDINGS, INC. | 0% | 1,000 | -90% | 0% | $650 |
| WELLS FARGO & COMPANY/MN | 0% | 500 | 0% | $325 | |
| BARCLAYS PLC | 0% | 90 | 0% | $59 | |
| MORGAN STANLEY | 0% | 23 | 0% | $15 | |
| Caitong International Asset Management Co., Ltd | 0% | 1 | 0% | 0% | $1 |
| BlackRock, Inc. | 0% | 0 | -100% | $0 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
9
Headline period
Q2 2026
Rows shown
1-9 of 9
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 403,072 | $405,582 | +$49,224 | $1.01 | 3 |
| 2026 Q2 | 14,145,277 | $9,195,137 | -$65,363 | $0.65 | 19 |
| 2026 Q1 | 14,247,638 | $8,828,728 | +$4,455,955 | $0.62 | 13 |
| 2025 Q4 | 6,861,177 | $6,861,177 | -$1,583,956 | $1.00 | 17 |
| 2025 Q3 | 8,357,159 | $16,966,429 | +$16,255,712 | $2.03 | 16 |
| 2025 Q2 | 227,492 | $989,589 | +$573,842 | $4.35 | 7 |
| 2025 Q1 | 105,008 | $97,657 | -$115,519 | $0.93 | 6 |
| 2024 Q4 | 200,884 | $230,191 | +$180,602 | $1.15 | 11 |
| 2024 Q3 | 41,238 | $57,016 | +$57,016 | $1.39 | 7 |